Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-08-27 / Biomed Res Int 2015;2015:842923Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-08-27 / J. Neurooncol. 2015 Oct;125(1):65-74HN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway
/in International Publications, Newcastle Disease Virus /von 2015-08-26 / Appl. Biochem. Biotechnol. 2015 Oct;177(4):940-56Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-94Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
/in Breast Cancer, Dendritic Cells, International Publications /von 2015-08-13 / Clin Transl Oncol 2016 Jan;18(1):82-7Therapeutic hyperthermia: The old, the new, and the upcoming
/in Hyperthermia, International Publications /von 2015-08-08 / Crit. Rev. Oncol. Hematol. 2016 Jan;97:56-64Dendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-08-07 / J. Neurosurg. 2015 Oct;123(4):989-97Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2015-08-01 / Transl Oncol 2015 Aug;8(4):327-38
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de